Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

ZYVOX

Drug and asset intelligence for ZYVOX with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Pfizer →

Recent signals(2)

RegulatoryJune 21, 2026

FDA Approves Supplemental Applications for ZYVOX by Pfizer

The FDA has approved supplemental applications for ZYVOX (linezolid), indicating ongoing support for this antibiotic.

ClinicalJune 18, 2026

Study on Host-Pathogen Interaction with Staphylococcus aureus Using Lymphoid Organoids

A study is being conducted to understand the interaction between Staphylococcus aureus and human cells using tonsil tissues.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Pfizer — ZYVOX

Monitor for any upcoming clinical data or additional approvals related to ZYVOX and its competitors.

June 21, 2026 · N/A

Topline Data

Pfizer — Zyvox

Results from the study that may identify novel mechanisms of infection or new treatment strategies for S.

June 18, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Antibiotic →
Infectious Disease →
Infectious Disease · Antibiotic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.